NERVIANO Medical Sciences S.r.l. Announces Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

NERVIANO, 18 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the Company’s Phase I/II clinical study of NMS-01940153E in Hepatocellular carcinoma (HCC) will be reported in an oral presentation by Dr. Maria Reig at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2022) which will be held October 26-28, 2022 at the CCIB in Barcelona.

Details of the upcoming oral presentation are as follows:

Title: NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma
Presenter: Dr. Maria Reig, Head of Liver Oncology Unit, Hospital Clinic Barcelona, Barcelona, Spain
Session: Plenary Session 7
Session Date/Time: Friday, October 28, 2022, 3:00 – 4:30 p.m. CET
Location: Room 111 + 112

The data are embargoed until the day of the presentation. A copy of the oral presentation will be available at www.nervianoms.com following presentation at the meeting.

About NMS-01940153E (NMS-153)

Primary liver cancer is the sixth most common neoplasm and among the leading cause of cancer-related death worldwide. HCC constitutes 80-90% of all primary liver cancers. Its incidence is increasing and will soon surpass one million annual cases worldwide. Most HCC cases are diagnosed at advanced stages and despite the recent approval of new therapeutic agents such as checkpoint inhibitors, there is a high unmet medical need.

NMS-153 is a highly potent and selective inhibitor of the MPS1 kinase, which is a mitotic regulator frequently overexpressed and activated in cancer. NMS-153 showed a broad preclinical activity in different tumor types, including HCC.

MPSA-153-001 is a Phase I/II study of NMS-153 administered as single agent in treatment experienced, unresectable HCC patients. The trial is currently open for enrollment.

About Nerviano Medical Sciences

Nerviano Medical Sciences S.r.l. (NMS Srl) is focused on discovery and clinical development of small-molecule new chemical entities (NCEs) for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized...
medicines to cancer patients. Our current pipeline consists of NCEs originating from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in-house and with partners.

NMS Srl combines the flexibility of a biotech with the quality of a big Pharma. Our experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing).

A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib.

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development.

About NMS Group

**NMS Group** is the largest oncological R&D company in Italy. More than half of our 400 employees are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group’s innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug products supporting clinical developments and commercialization.

Media contact: Sidney Dung [Sidney.dung@nmsgroup.it](mailto:Sidney.dung@nmsgroup.it)